IRNF App vs Tempus ECG-Low EF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

IRNF App

by Apple

Tempus ECG-Low EF

by Tempus AI

AI Verdict

Tool A is a consumer-facing application for detecting irregular heart rhythms suggestive of Atrial Fibrillation using a wearable device, providing notifications directly to the user. In contrast, Tool B is a clinical diagnostic aid for healthcare professionals, analyzing 12-lead ECGs to identify signs associated with low left ventricular ejection fraction. While both leverage AI in cardiology, their distinct target users, data inputs, and specific clinical objectives make them adjacent rather than direct competitors.

Choose IRNF App if…

Choose the IRNF App if you are an individual seeking an accessible, over-the-counter solution for personal monitoring of irregular heart rhythms suggestive of Atrial Fibrillation. This tool is ideal for proactive self-management and early notification outside of a traditional clinical setting, leveraging your existing Apple Watch and iPhone for continuous, passive data collection.

View IRNF App →

Choose Tempus ECG-Low EF if…

Choose Tempus ECG-Low EF if you are a clinician in a healthcare facility requiring AI-powered assistance to identify patients 40 years or older at risk of heart failure by analyzing standard 12-lead ECG recordings. This software is best suited for integrating into clinical diagnostic workflows to aid in the early detection of signs associated with low left ventricular ejection fraction, supporting further clinical evaluation.

View Tempus ECG-Low EF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	IRNF App	Tempus ECG-Low EF
Pricing	Free	Contact vendor
Deployment	Mobile (iOS, watchOS)	Software, integrated into healthcare facility workflows
BAA Available	No AI-estimated	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

IRNF App

Tool A is designed as an over-the-counter mobile medical application for personal devices, emphasizing intuitive onboarding and integration with the Apple Health app. Its direct-to-consumer nature prioritizes ease of use for a broad, non-clinical audience.

Clinical Value

Tempus ECG-Low EF

Tool B provides an AI-powered diagnostic aid for clinicians, analyzing 12-lead ECGs to detect signs of low LVEF, a critical indicator for heart failure. This directly supports clinical decision-making for a severe condition within a professional healthcare setting.

Pricing & Value

IRNF App

Tool A is offered as a free feature included with compatible Apple Watch and iPhone models, providing significant health monitoring value at no additional cost to the user. Tool B requires contacting the vendor for pricing, implying a potentially substantial cost for healthcare facilities.

Enterprise Readiness

Tempus ECG-Low EF

Tool B is explicitly designed for integration into healthcare facility workflows, offering HIPAA compliance and a Business Associate Agreement (BAA). Tool A is a consumer-facing mobile application and does not offer enterprise-level compliance or integration features.

Innovation

Tempus ECG-Low EF

While Tool A innovated by bringing irregular rhythm detection to mass-market wearables, Tool B represents a significant advancement by applying AI to standard 12-lead ECGs to detect signs of low LVEF. This capability extracts complex diagnostic insights from a common test, which traditionally required more advanced imaging.

Support & Docs

IRNF App

Tool A benefits from Apple's extensive and well-established support ecosystem, including comprehensive online resources, educational materials, and direct customer service channels. While Tool B would offer professional support for healthcare facilities, specific details on its documentation and support infrastructure are not provided in the available data.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	IRNF App	Tempus ECG-Low EF
Name	IRNF App	Tempus ECG-Low EF
Company	Apple	Tempus AI
Primary Detection/Purpose	Detects irregular heart rhythms suggestive of Atrial Fibrillation (AFib) and notifies users.	Analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%) in patients 40 years or older at risk of heart failure.
Input Data/Method	Pulse rate data analysis using Apple Watch PPG sensor	Analyzes resting, non-ambulatory 12-lead ECG recordings
Intended Use/Setting	Over-the-counter (OTC) use	Clinical diagnostic settings at healthcare facilities, aids clinicians

Videos

Demos, reviews, and walkthroughs featuring IRNF App and Tempus ECG-Low EF.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into a physician's existing clinical workflow for cardiac screening and diagnosis?

The IRNF App is a patient-facing tool that provides notifications to the user, who then shares this information with their physician, fitting into a proactive, patient-initiated screening workflow. Tempus ECG-Low EF integrates directly into healthcare facility workflows, analyzing 12-lead ECGs as part of a diagnostic process to aid clinicians in further evaluation for low LVEF.

What are the differences in EHR integration capabilities and how is patient data managed for each tool?

The IRNF App integrates with the Apple Health app for data storage and management, allowing users to share a PDF of results with physicians, but it does not have a BAA. Tempus ECG-Low EF is designed to work with existing ECG platforms and EHRs, enabling advanced AI deployment and insights directly within clinical workflows, and it is HIPAA compliant with BAA availability.

What specific clinical insights do these tools provide, and for which patient populations are they most relevant?

The IRNF App detects irregular heart rhythms suggestive of Atrial Fibrillation (AFib) using pulse rate data from Apple Watch, intended for users 22 years and older without a previous AFib diagnosis. Tempus ECG-Low EF analyzes 12-lead ECGs to detect signs associated with low Left Ventricular Ejection Fraction (LVEF u226440%) in patients 40 years or older at risk of heart failure, providing a binary output to aid clinicians in further evaluation.

What is the expected learning curve for clinical staff to effectively utilize each tool?

The IRNF App is an over-the-counter (OTC) feature primarily used by patients, with onboarding and educational materials provided to users, implying minimal direct staff training for its use. Tempus ECG-Low EF is a software integrated into healthcare facility workflows, suggesting a learning curve for clinical staff to incorporate its AI-powered ECG analysis into their diagnostic processes, though it is designed to fit seamlessly into existing workflows.

Do these tools offer any audit-trail features or mechanisms for tracking their use and findings?

The IRNF App provides a history of AFib notifications within the Apple Health app, allowing users to track past alerts and share data by exporting health data. Tempus ECG-Low EF provides a binary output (Low LVEF Detected / Not Detected) to aid clinicians, and its integration into facility workflows would typically leverage existing hospital system audit capabilities for ECG analysis.

How do multi-site healthcare organizations approach the rollout and management of these tools?

The IRNF App is a consumer-facing feature on personal devices, meaning its 'rollout' is individual patient adoption, not a healthcare system deployment. Tempus ECG-Low EF is a software integrated into healthcare facility workflows, suggesting a more structured deployment process across multiple sites, requiring coordination for software integration and staff training.

What are the accuracy and sensitivity considerations for each tool in a clinical context?

The IRNF App's irregular rhythm notification feature has shown varying sensitivity (e.g., 21.4% in one study) but high specificity (100%) for detecting AFib, and is intended for pre-screening rather than diagnosis. Tempus ECG-Low EF demonstrated a sensitivity of 86% and specificity of 83% for classifying patients with low LVEF, with a negative predictive value of 98%, and is intended to aid clinicians in further evaluation, not as a standalone diagnostic tool.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring IRNF App or Tempus ECG-Low EF

Backers

Who funded each tool's parent company.

IRNF App

Transformer VC